Neurocrine Biosciences Inc NB3-FF:Frankfurt Stock Exchange

RT Quote | Exchange | EUR
Last | 06/11/21 CEST
81.90quote price arrow up+1.46 (+1.82%)
52 week range
72.36 - 120.00

...

Loading . . .
  • Open81.90
  • Day High81.90
  • Day Low81.90
  • Prev Close80.44
  • 52 Week High120.00
  • 52 Week High Date07/09/20
  • 52 Week Low72.36
  • 52 Week Low Date05/06/21

Key Stats

  • Market Cap9,318.64M
  • Shares Out94.5M
  • 10 Day Average Volume4.67
  • Dividend-
  • Dividend Yield-
  • Beta
  • YTD % Change7.96

KEY STATS

  • Open81.90
  • Day High81.90
  • Day Low81.90
  • Prev Close80.44
  • 52 Week High120.00
  • 52 Week High Date07/09/20
  • 52 Week Low72.36
  • 52 Week Low Date05/06/21
  • Market Cap9,318.64M
  • Shares Out94.5M
  • 10 Day Average Volume4.67
  • Dividend-
  • Dividend Yield-
  • Beta
  • YTD % Change7.96

RATIOS/PROFITABILITY

  • EPS (TTM)3.50
  • P/E (TTM)23.40
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Neurocrine Biosciences Inc

There is no recent news for this security.

Profile

MORE
Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2)...
William Rastetter Ph.D.
Non-Executive Chairman
Kevin Gorman Ph.D.
Chief Executive Officer
Matthew Abernethy CPA
Chief Financial Officer
Address
12780 El Camino Real
San Diego, CA
92130-2042
United States